Re-Vana Therapeutics Raises USD11.9M in Series A Funding

Re-Vana Therapeutics Ltd, a Belfast, Northern Ireland, UK-based specialty drug delivery company developing sustained-release therapeutics for the treatment of vision-threatening ocular diseases, raised $11.9 million in Series A funding led by Visionary Ventures with participation from ExSight Ventures, InFocus Capital Partners, Qubis Ltd, Co-Fund NI, and TechStart Ventures. The company intends to use the proceeds for the development of its novel and proprietary photo-crosslinked EyeLief®, EyeLief-SD™ and OcuLief® biodegradable drug delivery technologies and for the expansion of operations and development teams.

Re-Vana Therapeutics Secures $11.9 Million in Series A Funding

Re-Vana Therapeutics Ltd, a Belfast, Northern Ireland, UK-based specialty drug delivery company developing sustained-release therapeutics for the treatment of vision-threatening ocular diseases, closed its Series A round with $11.9m in funding. Founded in 2016 as a spin-out from Queen’s University Belfast, Northern Ireland, Re-Vana Therapeutics is a specialty ocular therapeutic and drug delivery company with headquarters located in Belfast and a U.S.-based office, Re-Vana Therapeutics, Inc., in Tampa, Florida. it is currently developing sustained release ophthalmic therapeutics aimed at reducing the frequency of intravitreal injections required to treat a wide range of retinal diseases, including neovascular age-related macular degeneration (wet AMD). In addition, its proprietary photo-crosslinked sustained-release technology may enable the development of a broad range of novel, sustained release products applicable to a variety of therapeutic areas.

A Belfast, Northern Ireland-based specialty drug delivery company developing sustained-release therapeutics for the treatment of vision-threatening ocular diseases.

3 years ago

Re-Vana Therapeutics Secures $11.9 Million in Series A Funding

ProblemHealthcare

Solution

Covered on